Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study

BMC Public Health

Table 4 Sensitivity analysis of horizontal equity in incidence of preventive statin therapy: Three alternative need-weights (need-proxies) in the need-standardized analyses ^a : Myocardial infarction (MI), combined MI-stroke or CVD-death ^b

SEP indicator^c	Age	Horizontal Inequity gradient (IRR)^ddependent on need-weights
		MI		MI-stroke		CVD-death
		Male	Female	Male	Female	Male	Female
Income	40-64	1.17	1.23	1.18	1.15	1.39	1.36
	65-84	1.17	1.20	1.15	1.10	1.29	1.23
Educational level	40-64	1.19	1.24	1.18	1.11	1.33	1.22
	65-84	1.21	1.21	1.15	1.11	1.23	1.29

a) Need-standardized Poisson analyses see notes Table 3.
b) Myocardial infarction (MI) as need-weight in the basic analyses. Two alternative CVD need: Incidence of MI and stroke as combined endpoint during 2002–2006, and CVD-death (i.e., MI, stroke and aorta-aneurism) during 2002–2008.
c) Indicators of socio-economic position (SEP): cf. notes Tables 1 & 3.
d) Horizontal Inequity (HIE) gradient: The relative change in need-standardized statin incidence for each increase in SEP, i.e., the estimated overall linear trend.

ISSN: 1471-2458